In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on OncoSec Medical (ONCS), with a price target of $5. The company’s shares opened today at $0.84, close to its 52-week low of $0.68.
McCarthy wrote:
“OncoSec announced updated data from the P2b KEYNOTE-695 study of TAVO (DNA-based IL-12) in combination with Keytruda in metastatic melanoma, which builds on the prior report (N=9) from the SITC meeting, where two patients achieved a partial response (PR) at week 12.”
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.3% and a 28.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Based on OncoSec Medical’s latest earnings release for the quarter ending July 31, the company reported a quarterly GAAP net loss of $12.44 million. In comparison, last year the company had a GAAP net loss of $5.9 million.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.
Read More on ONCS:
